Telix Pharmaceuticals

是其中之一......

• S&P/ASX200.

Telix Pharmaceuticals 是一家在股票代码 TLX (AU) 下上市的公司。

Telix Pharmaceuticals 在 3 个国家有直接业务。

Telix Pharmaceuticals 拥有 3家子公司，其中包括 Telix Pharmaceuticals Americas、Telix Pharmaceuticals APAC 和 Telix Pharmaceuticals EMEA。

查看带有其 34 名主要高管的组织结构图

Telix Pharmaceuticals 搜索最多的简介

• Christian Behrenbruch, Director, Group Managing Director and Chief...
• Mark Nelson, Non-Executive Director
• Andreas Kluge, Non-Executive Director

高管在Telix Pharmaceuticals变化

• Darren Patti 曾任 US Chief Operating Officer and General Manager, Americas, 现升职为 Group Chief Operating Officer  (新闻发布的2024三月13号).
• Colin Hayward, Chief Medical Officer, 将于 202312月31 退休  (新闻发布的2023十二月21号).
• David Cade 曾任 Chief Executive Officer, Asia-Pacific, 将于 20241月1 升职为 Group Chief Medical Officer  (新闻发布的2023十二月20号).

创建提醒
跟踪 Telix Pharmaceuticals 的高管变动

Telix Pharmaceuticals 拥有 1,860 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。

Popular M&A news in 药店

• MedMen has filed for bankruptcy protection  (公布2024四月28号).
• AstraZeneca has announced the acquisition of Fusion Pharma  (公布2024三月23号).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (公布2024三月19号).

药店 行业的其他推荐联系人

• Ferring Pharmaceuticals 企业 Jean-Frédéric Paulsen - Executive Chairman of the Board
• Amolyt Pharma 企业 Thierry Abribat - Chief Executive Officer
• Menarini Group 企业 Lucia Aleotti - Director

了解更多有关药店行业的信息 >

Telix Pharmaceuticals 的最新新闻稿

• Telix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform  | Telix Pharmaceuticals
• TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation   | Telix Pharmaceuticals
• TLX250-CDx (Zircaix®) Recognised in EAU Guidelines as an Emerging Technology for the Management of RCC (Kidney Cancer)  | Telix Pharmaceuticals
• Q1 2024 Revenue and Business Update  | Telix Pharmaceuticals
• Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia | Telix Pharmaceuticals
• Telix Completes Acquisition of IsoTherapeutics | Telix Pharmaceuticals
• Telix GM 2024 | Telix Pharmaceuticals
• Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU  | Telix Pharmaceuticals
• World First Use of Lightpoint’s SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain | Telix Pharmaceuticals
• First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent | Telix Pharmaceuticals
• View more press releases Close

关于 Telix Pharmaceuticals 的社交媒体

• Telix Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Telix Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Christian Behrenbruch

致电Telix Pharmaceuticals，电话：+61 44...

查看组织结构图

Register to receive your alert

报告错误